Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 11/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21130412 | 1.00 | PDE4D (0.44) | PDE4DSCN9AHTR2AHTR2CHTR2B | |
| SCHEMBL21062018 | 0.83 | PDE4D (0.41) | PDE4DHSD17B10NPSR1MAPK1MEN1 | |
| SCHEMBL30712007 | 0.83 | PDE4D (0.41) | PDE4DHSD17B10NPSR1MAPK1MEN1 | |
| SCHEMBL23098518 | 0.76 | PDE4D (0.43) | PDE4DSCN9AHTR2AHTR2CHTR2B | |
| SCHEMBL23084497 | 0.74 | SCN9A (0.42) | PDE4DSCN9AHTR2AHTR2CHTR2B | |
| SCHEMBL21062072 | 0.73 | PDE4D (0.39) | PDE4DHSD17B10NPSR1MAPK1MEN1 | |
| SCHEMBL30712011 | 0.73 | PDE4D (0.39) | PDE4DHSD17B10NPSR1MAPK1MEN1 | |
| SCHEMBL2298279 | 0.72 | SCN9A (0.50) | PDE4DSCN9AHTR2AHTR2CHTR2B | |
| SCHEMBL26968894 | 0.70 | PDE4D (0.36) | PDE4DSCN9AHTR2AHTR2CHTR2B | |
| SCHEMBL26968848 | 0.69 | PDE4D (0.51) | PDE4DSCN9AHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400578-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2024-12-05 | — | — | US | disclosed |
| CN-111727191-B | Substituted azetidine dihydro-thienopyridines and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-01-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400578-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE2A, PDE3A, PDE3B | PDE4D 12/4885SCN9A 567/4885HTR2A 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.